Galectin Therapeutics Receives U.S. Patent for Potential Ground-Breaking Treatment for Chronic Liver Disease With Fibrosis (Scarring) and Cirrhosis
Published: Jul 23, 2012
NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of issuance from the U.S. Patent and Trademark Office for Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies”. The patent covers key methods of derivation and use for the Company’s carbohydrate-based galectin inhibitor compound for use in patients with chronic liver disease associated with the development of fibrosis, established liver fibrosis or end-stage scarring, or cirrhosis. Fibrotic disease of the liver is highly prevalent in the population because all chronic liver disease of multiple causes (e.g., viral hepatitis, fatty liver, alcohol) results in fibrosis of the liver and there are no currently approved pharmaceutical therapies.